Bears, Buffett, and Big Pharma Define the Day

Hertz: Short Sellers Have No Exit

HTZ remains the most extreme short position in the market. Short interest sits at 65.4% of free float. Zero shares are available to borrow. The stock is down 56% year-to-date. Options flow confirms the bearish consensus — put demand is high, and the 12.1 days-to-cover means any squeeze would be violent. This is a name to watch closely.

Berkshire Deploys Its Cash Mountain

Berkshire Hathaway is today's biggest macro story. New CEO Greg Abel is spending down the firm's giant cash pile, according to AP. Berkshire reported Q2 results this morning. Markets are watching closely to see where Abel is putting Buffett's billions — and whether it signals confidence in current valuations.

Pharma Rises, Fintech Falls

Analysts are split on sectors today. ABBV and AMGN both saw target price upgrades. Amgen is RSI 72 — overbought — and short interest is just 2.4% of free float. Pharma bulls are in control. On the other side, FIS took a consensus cut to $51.09. The fintech carries 14 sell ratings, more than buys. That bearish skew is hard to ignore.

Insiders Head for the Door

Insider selling is widespread today. Charles Schwab filed over $37M in sales at SCHW this week. Life Time Group's CEO Bahram Akradi sold $19.5M at LTH on August 4. His CFO and a division president filed the same day. Three C-suite sellers in one filing wave is a notable signal.

Europe: Vestas in Focus

Danish wind giant Vestas Wind Systems reports early Wednesday. Energy transition names remain in the spotlight as oil price pressure weighs on analyst targets — FANG also saw a trim today amid Permian headwinds.